NCT07677631

Brief Summary

The Emotional Allodynia Questionnaire (AEQ) is an 11-item self-report instrument that measures disproportionate emotional reactivity to low-intensity interpersonal cues(perceived unresponsiveness, exclusion, loss of reciprocity), a pattern termed emotional allodynia. It was preliminarily validated in a single-center fibromyalgia sample. PEARL (validation phase) is a multicenter, prospective, observational psychometric validation study that (1) replicates the internal structure and convergent validity of the AEQ in an independent fibromyalgia sample, (2) tests its known-groups (discriminative) accuracy in separating fibromyalgia from non-fibromyalgia chronic pain of defined nociceptive or neuropathic origin, expressed as the area under the ROC curve (AUC), and (3) assesses test-retest reliability. There is no intervention.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
423

participants targeted

Target at P75+ for all trials

Timeline
12mo left

Started Sep 2025

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Sep 2025Aug 2027

Study Start

First participant enrolled

September 10, 2025

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 20, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 1, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2027

Last Updated

July 1, 2026

Status Verified

June 1, 2026

Enrollment Period

1.7 years

First QC Date

June 20, 2026

Last Update Submit

June 24, 2026

Conditions

Keywords

Emotional Allodynia QuestionnaireFibromyalgiaNociplastic painPsychometric validationCentral sensitizationEmotion regulation

Outcome Measures

Primary Outcomes (3)

  • Internal consistency of the Emotional Allodynia Questionnaire (AEQ) in fibromyalgia cases

    Internal consistency reliability of the AEQ, an 11-item self-report questionnaire (total score range 0-44), in fibromyalgia cases, assessed using Cronbach's alpha and McDonald's omega, each reported with 95% confidence intervals.

    Baseline (T0)

  • Factorial structure of the Emotional Allodynia Questionnaire (AEQ)

    Latent factor structure of the 11-item AEQ self-report questionnaire, assessed by exploratory factor analysis and a single-factor confirmatory factor analysis (CFA). Reported as CFA model fit indices: comparative fit index (CFI), Tucker-Lewis index (TLI), root mean square error of approximation (RMSEA), and standardized root mean square residual (SRMR).

    Baseline (T0)

  • Known-groups discriminative accuracy of the AEQ (AUC)

    Discriminative accuracy of the AEQ total score (11-item self-report questionnaire) in distinguishing fibromyalgia cases from non-fibromyalgia chronic pain controls, reported as the area under the receiver operating characteristic (ROC) curve (AUC, range 0-1) with 95% confidence interval, tested against a null value of 0.70.

    Baseline (T0)

Secondary Outcomes (6)

  • Convergent validity of the Emotional Allodynia Questionnaire (AEQ)

    Baseline (T0)

  • Discriminant validity of the Emotional Allodynia Questionnaire (AEQ) versus the DERS

    Baseline (T0)

  • Test-retest reliability of the Emotional Allodynia Questionnaire (AEQ) total score

    Baseline (T0) and retest at approximately 40 days (plus or minus 10 days)

  • AEQ score distribution across AEQ-CSI median-split phenotypes

    Baseline (T0)

  • Floor and ceiling effects of the Emotional Allodynia Questionnaire (AEQ)

    Baseline (T0)

  • +1 more secondary outcomes

Other Outcomes (1)

  • Concordance between AEQ-CSI phenotypes and data-driven clusters

    Baseline (T0)

Study Arms (2)

Fibromyalgia cases

Adults with fibromyalgia diagnosed per the 2016 ACR criteria.

Non-fibromyalgia chronic pain controls

Adults with chronic non-cancer pain of defined nociceptive or neuropathic origin who do not meet the 2016 ACR criteria for fibromyalgia.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults attending Italian tertiary pain outpatient services. Cases are identified from fibromyalgia services; controls are identified among patients attending the same services for chronic non-cancer pain of defined nociceptive or neuropathic origin. Consecutive eligible patients are considered for enrollment.

You may qualify if:

  • Age 18 years or older
  • Clinical diagnosis of fibromyalgia confirmed according to the 2016 revision of the ACR criteria
  • Chronic non-cancer pain for at least 3 months
  • Ability to understand and independently complete self-report questionnaires in Italian
  • Willingness to provide written informed consent

You may not qualify if:

  • Active oncological disease or cancer-related pain
  • Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder (assessed by clinical history)
  • Severe cognitive impairment precluding questionnaire completion
  • Inability to understand or complete questionnaires in Italian
  • CONTROLS (non-fibromyalgia chronic pain)
  • Age 18 years or older
  • Chronic non-cancer pain for at least 3 months with a defined nociceptive or neuropathic generator (e.g., radiologically or surgically documented degenerative, structural, or post-surgical musculoskeletal pain, or neuropathic pain with an identifiable neurological lesion or disease)
  • Not meeting the 2016 ACR criteria for fibromyalgia
  • Ability to understand and independently complete self-report questionnaires in Italian
  • Willingness to provide written informed consent
  • Diagnosis of fibromyalgia or another recognized nociplastic primary pain condition (e.g., primary chronic widespread pain)
  • Active oncological disease or cancer-related pain
  • Any current or past psychiatric diagnosis except Major Depressive Disorder and Panic Disorder
  • Severe cognitive impairment precluding questionnaire completion
  • Inability to understand or complete questionnaires in Italian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Pain Unit, Policlinico di Bari, University of Bari Aldo Moro (coordinating center)

Bari, 70124, Italy

RECRUITING

Anesthesia and Pain Therapy Unit, IRCCS AOSP di Bologna, Policlinico S. Orsola-Malpighi

Bologna, 40138, Italy

NOT YET RECRUITING

Department of Medical Sciences and Public Health, University of Cagliari

Cagliari, Italy

NOT YET RECRUITING

Department of Women, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli

Naples, Italy

NOT YET RECRUITING

Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona

Verona, Italy

NOT YET RECRUITING

Related Publications (1)

  • Corriero A, Giglio M, Pilolla A, Galdini F, Mucci O, Vurro M, Fornarelli F, Di Venosa C, Trerotoli P, Puntillo F. The Emotional Allodynia Questionnaire: Preliminary Validation and Clinical Phenotyping in Fibromyalgia. J Pain Res. 2026 Jun 3;19:607309. doi: 10.2147/JPR.S607309. eCollection 2026.

    PMID: 42261300BACKGROUND

MeSH Terms

Conditions

FibromyalgiaChronic PainNociplastic PainEmotional Regulation

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSelf-ControlSocial BehaviorBehavior

Study Officials

  • Alberto Corriero, MD, PhD

    University of Bari Aldo Moro, Pain and ICU Section

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alberto Corriero, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 20, 2026

First Posted

July 1, 2026

Study Start

September 10, 2025

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

August 1, 2027

Last Updated

July 1, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Individual participant data (IPD) will not be shared publicly. Under Italian data protection regulations and the EU General Data Protection Regulation (GDPR), participant-level data from this study cannot be made publicly available. The working dataset is pseudonymized and held on secure institutional systems. De-identified data supporting the main findings may be made available from the corresponding author upon reasonable request, subject to a data-sharing agreement and compliance with applicable data-protection requirements.

Locations